Stock Events

Insulet 

$193.51
59
-$1.52-0.78% Friday 20:00

Statistics

Day High
196.94
Day Low
191.94
52W High
223.56
52W Low
125.82
Volume
510,272
Avg. Volume
791,601
Mkt Cap
13.57B
P/E Ratio
36.93
Dividend Yield
-
Dividend
-

Upcoming

31
OCT
Earnings
 

Earnings

31OctConfirmed
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
0.11
0.94
1.76
2.59
Expected EPS
0.75838
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PODD. It's not an investment recommendation.
Alphabet
71293
GOOGL
Apple
62564
AAPL
Microsoft
58315
MSFT
Amazon
53730
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Tandem Diabetes Care
TNDM
Mkt Cap2.45B
Tandem Diabetes Care, Inc. competes directly with Insulet by offering insulin pump therapy for diabetes management, which is a direct alternative to Insulet's Omnipod system.
Medtronic
MDT
Mkt Cap105.2B
Medtronic plc is a major competitor in the insulin pump market, offering a range of products that compete with Insulet's offerings for diabetes management.
Dexcom
DXCM
Mkt Cap27.95B
DexCom, Inc. provides continuous glucose monitoring (CGM) systems that are often used in conjunction with insulin pumps like those offered by Insulet, making them a competitor in the broader diabetes management space.
Abbott Laboratories
ABT
Mkt Cap189.14B
Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with the integrated diabetes management solutions provided by Insulet.
Insulet
PODD
Mkt Cap12.76B
Insulet Corporation is listed as its own competitor due to an error. Please disregard this entry.
Senseonics
SENS
Mkt Cap202.18M
Senseonics Holdings, Inc. offers the Eversense CGM system, which competes in the diabetes management market by providing an alternative to the CGM solutions that can be used with Insulet's products.
Novo Nordisk
NVO
Mkt Cap452.48B
Novo Nordisk A/S is a leading provider of insulin and other diabetes care products that, while not a direct competitor in the insulin pump market, competes in the broader diabetes management space.
Sanofi
SNY
Mkt Cap132.87B
Sanofi provides a range of diabetes care solutions, including insulin therapies that compete with the insulin management solutions offered by Insulet.
Mannkind
MNKD
Mkt Cap1.39B
MannKind Corporation offers Afrezza, an inhaled insulin, providing a non-injectable alternative to insulin delivery that competes with traditional pump therapies like those offered by Insulet.

Analyst Ratings

229$Average Price Target
The highest estimate is $260.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
73%
Hold
27%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Show more...
CEO
Shacey Petrovic
Employees
3000
Country
US
ISIN
US45784P1012
WKN
000A0MQX8

Listings

XNAS
US
PODD
MX
MX
PODD.MX
F
DE
GOV.F
SA
BR
P2OD34.SA